Characterization of Fluoroquinolone Resistance among Veterinary Isolates of Avian Escherichia coli

DAVID G. WHITE,1,2* LAURA J. V. PIDDOCK,3 JOHN J. MAURER,4 SHAOHUA ZHAO,2 VITO RICCI,3 AND STEPHAN G. THAYER4

Department of Veterinary and Microbiological Sciences, North Dakota State University, Fargo, North Dakota; Division of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom; Department of Avian Medicine, University of Georgia, Athens, Georgia; and Division of Animal and Food Microbiology, Center for Veterinary Medicine, U.S. Food and Drug Administration, Laurel, Maryland2

Received 6 April 2000/Returned for modification 21 June 2000/Accepted 10 July 2000

Fluoroquinolone-resistant avian Escherichia coli isolates from northern Georgia were investigated for gyrA and parC mutations. All isolates contained a mutation in GyrA replacing Ser83 with Leu; seven isolates also contained mutations replacing Asp87 with either Gly or Tyr. Random amplified polymorphic DNA analysis revealed that quinolone-resistant E. coli isolates were genetically diverse.

Colibacillosis continues to significantly contribute to increased mortality and economic losses in the poultry industry (1, 4, 6, 11). Sarafloxacin and enrofloxacin were approved in 1995 and 1996 in the United States for veterinary use to help control morbidity and mortality associated with Escherichia coli-related colibacillosis infections (14).

Quinolone resistance mechanisms employed by gram-negative bacteria include chromosomal mutations that reduce membrane permeability and decrease drug accumulation or alter DNA topoisomerases (9, 12, 17, 22, 23, 25). Clinical resistance to fluoroquinolones in E. coli, however, is mostly associated with mutations that result in amino acid changes in the A subunit (gyrA) and the B subunit (gyrB) of the DNA gyrase and in the parC-encoded subunit of topoisomerase IV (5, 8, 17, 18, 20, 23, 25).

This study was undertaken to investigate the genetic mechanisms involved in the emergence of bacterial fluoroquinolone resistance among pathogenic avian E. coli isolates. Furthermore, isolates were genetically characterized via random amplified polymorphic DNA (RAPD) analysis to determine if fluoroquinolone resistance was associated with specific E. coli clones. Fluoroquinolone resistance was surveyed among avian E. coli organisms isolated at the Poultry Diagnostic and Research Center (PDRC), University of Georgia, during a 37-month period from May 1996 to June 1999 (Fig. 1). Five hundred thirty-five E. coli isolates from clinical cases of avian colibacillosis were identified at the PDRC during this time. The percentage of sarafloxacin-resistant avian E. coli isolates steadily increased from 15% in 1996 to 40% in 1999 (Fig. 1). Dual resistance to sarafloxacin and enrofloxacin increased from 9% in 1997 to 30% in 1999.

Antimicrobial susceptibilities of 29 nalidixic acid-resistant avian E. coli isolates were determined with agar dilution and broth microdilution methods and interpreted according to the National Committee for Clinical Laboratory Standards (NCCLS) guidelines (15, 16). The majority of E. coli isolates were also resistant to several other antimicrobials tested, particularly sulphonmethoxazole (n = 27), tetracycline (n = 25), streptomycin (n = 24), gentamicin (n = 18), and ampicillin (n = 16). Resistance to the cephalosporins cephalothin (n = 6) and cefotiofur (n = 4) was observed as well. Additionally, nine E. coli isolates were resistant to chloramphenicol. Sixty-six percent (19 of 29) of quinolone-resistant E. coli isolates exhibited multiple resistance to five or more antimicrobials. MICs of nalidixic acid, enrofloxacin, sarafloxacin, and ciprofloxacin were then determined using an agar plate dilution method (Table 1). The MIC of the antibiotic was defined as the concentration (in micrograms per milliliter of agar) at which no more than two colonies were detected. Ninety-three percent (27 of 29) of the isolates required >256 μg of nalidixic acid/ml for inhibition, whereas two isolates required 64 μg/ml (resistant MIC breakpoint, ≥32 μg/ml). Three isolates required 32 μg of enrofloxacin/ml (resistant MIC breakpoint, ≥2 μg/ml) and 32 μg of sarafloxacin/ml (resistant MIC breakpoint, ≥0.25 μg/ml) for inhibition, and 13 isolates required 8 μg of sarafloxacin/ml or more for inhibition. Six isolates displayed intermediate susceptibility to ciprofloxacin (MIC = 2 μg/ml), and one isolate was cross-resistant to ciprofloxacin (MIC = 16 μg/ml; resistant MIC breakpoint, ≥4 μg/ml) as well as to enrofloxacin (≥32 μg/ml) and sarafloxacin (≥32 μg/ml).

Single-stranded conformational polymorphism PCR was employed to investigate the presence of mutations in the quinolone resistance-determining regions (QRDR) of the gyrA gene of DNA gyrase and the parC gene of topoisomerase IV as previously described (8). DNA sequencing of the gyrA and parC regions using previously described primers (8) confirmed the initial single-stranded conformation polymorphism analysis and interpretations (Table 1). All 29 nalidixic acid-resistant E. coli isolates contained the amino acid substitution Ser83 → Leu in the GyrA QRDR (Table 1). However, many of these E. coli isolates displayed variable fluoroquinolone susceptibility patterns. Seven isolates had the additional amino acid substitution Asp87 → Tyr (n = 2) or Asp87 → Gly (n = 5) within the GyrA QRDR. Twenty-three of 29 quinolone-resistant E. coli isolates assayed contained a silent mutation at Ser85 (AGC → AGT) in parC. However, no mutations conferring amino acid substitutions were detected in the QRDR of parC among the quinolone-resistant avian E. coli isolates (Table 1).

Fluoroquinolone-resistant avian E. coli isolates have also been previously identified in Saudi Arabia and Spain (3, 4). However, neither study identified the specific mutations associated with the fluoroquinolone resistance phenotypes. Additionally, Everett et al. observed that the majority of veterinary...
E. coli isolates (six of eight) resistant to fluoroquinolones isolated in the United Kingdom had mutations only in the QRDR of the gyrA gene (8). The present study suggests that avian E. coli isolates recovered from diseased poultry in the United States display similar resistance phenotypes as well as sharing common resistance mechanisms with those isolates previously described by other European investigators. However, we cannot exclude additional mechanisms that have yet to be identified which may contribute to fluoroquinolone resistance, especially in isolates with high-level resistance.

Avian E. coli isolates were further typed by RAPD using previously published primers (13). Grouping of E. coli isolates into each cluster or branch in the dendrogram correlated with similarities in their RAPD DNA pattern (Fig. 2). A total of 16 different clusters or RAPD types (RT) were identified from 184 avian E. coli isolates that have been previously described (13). The 29 fluoroquinolone-resistant avian E. coli isolates were typed by RAPD and could be assigned to six different RT groups: RT1, RT5, RT6, RT7, RT8, and RT10 (Fig. 2). The random association of fluoroquinolone-resistant avian E. coli isolates among multiple RTs indicates a genetically diverse population and suggests that fluoroquinolone resistance has appeared among independent chromosomal backgrounds and is not due to the emergence of particular resistant clonal genotypes.

This study reports the first occurrence of fluoroquinolone resistance in veterinary E. coli isolates recovered from clinical cases of avian colibacillosis in the United States. A marked increase in sarafloxacin and enrofloxacin resistance was observed among pathogenic avian E. coli in northern Georgia from 1996 to 1999. This trend coincides with the approval of these fluoroquinolones in 1995 and 1996 for treatment of E. coli-related poultry infections. Similar results have been seen among other pathogenic E. coli strains and most likely reflect the selection of antibiotic-resistant populations due to therapeutic use of antimicrobials (3, 4, 6, 7, 20, 24). There is mounting evidence that antimicrobial use in veterinary medicine may select for antimicrobial-resistant zoonotic bacterial pathogens (e.g., Salmonella and Campylobacter) (2, 7, 10, 19, 21). This has led to increased pressure to limit fluoroquinolones in animals to preserve the value of these drugs in the treatment of human infections (2, 10, 19, 21). However, the proposed linkage between fluoroquinolone use in agriculture and the occurrence of resistant human enteric bacterial pathogens is still being de-

### Table 1. GyrA and ParC mutations and fluoroquinolone susceptibility profiles of avian E. coli isolates

<table>
<thead>
<tr>
<th>No. of isolates</th>
<th>Mutation in:</th>
<th>MIC range (µg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>GyrA protein&lt;sup&gt;a&lt;/sup&gt;</td>
<td>ParC gene&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>18</td>
<td>Ser83 → Leu</td>
<td>AGC → AGT</td>
</tr>
<tr>
<td>4</td>
<td>Ser83 → Leu</td>
<td>None (wild type)</td>
</tr>
<tr>
<td>3</td>
<td>Ser83 → Leu; Asp87 → Gly</td>
<td>AGC → AGT</td>
</tr>
<tr>
<td>2</td>
<td>Ser83 → Leu; Asp87 → Gly</td>
<td>None (wild type)</td>
</tr>
<tr>
<td>2</td>
<td>Ser83 → Leu; Asp87 → Tyr</td>
<td>AGC → AGT</td>
</tr>
</tbody>
</table>

<sup>a</sup> MICs determined with agar plate dilution methods according to NCCLS guidelines (15, 16). Nal, nalidixic acid; Cip, ciprofloxacin; Enr, enrofloxacin; Sar, sarafloxacin.

<sup>b</sup> Amino acid substitution(s) in GyrA.

<sup>c</sup> Nucleotide substitution in the third position of the Ser58 codon.
bated (19). Regardless, the detection of fluoroquinolone bacterial resistance in a veterinary situation stresses the need for the judicious use of these antimicrobials.

We thank Marie Maier and Julie Sherwood for their technical assistance.

This work was supported by grants from the U.S. Poultry and Egg Association (to J.M., D.W., and L.J.V.P.) and USDA-NRRCGP grant 9902829 (to D.W., J.M., and S.Z.).

REFERENCES


